Zimmer Biomet HoldingsXSWX:ZBH +0.68%69 Days Payable is 52.89 as of Mar. 2026, which is 11% below its 10-year median of 59.35. GuruFocus rates XSWX:ZBH with a GF Score™ of 69/100 and a GF Value™ of CHF100.92 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks worse than 68.72% on this metric.
The historical rank and industry rank for Zimmer Biomet Holdings's Days Payable or its related term are showing as below:
XSWX:ZBH'
s Days Payable Range Over the Past 10 Years
Min: 36.42 Med: 59.35 Max: 73.12
Current: 47.2
During the past 13 years, Zimmer Biomet Holdings's highest Days Payable was 73.12. The lowest was 36.42. And the median was 59.35.
XSWX:ZBH's Days Payable is ranked worse than 68.72% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs XSWX:ZBH: 47.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZBH vs PEN, GMED, STE: Days Payable Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zimmer Biomet Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (XSWX:ZBH) has a Days Payable of 52.89 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zimmer Biomet Holdings and its competitors. This is 11% below median its historical median of 59.35. Over the past decade, Zimmer Biomet Holdings' Days Payable has ranged from 36.42 to 73.12. According to the industry distribution chart, Zimmer Biomet Holdings ranks #547 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 68.7%.
Is Zimmer Biomet Holdings' Days Payable too high?
Zimmer Biomet Holdings' current Days Payable of 52.89 is 11% below median its 10-year median of 59.35. Over the past 10 years, this metric has ranged from a low of 36.42 to a high of 73.12. The Medical Devices & Instruments industry median Days Payable is 68.14. Zimmer Biomet Holdings' value of 52.89 is 22.4% below this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #547 out of 796 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Days Payable compare to PEN and GMED?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #547 out of 796 companies for Days Payable. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median Days Payable is 68.14. Zimmer Biomet Holdings' value of 52.89 is 22.4% below this benchmark. Historically, Zimmer Biomet Holdings' own Days Payable has ranged from 36.42 to 73.12 over the past decade. While the company's 10-year median is 59.35 vs. the industry median of 68.14, Zimmer Biomet Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Days Payable of 52.89 is 22.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Days Payable is 52.89, which is 11% below median its own 10-year median of 59.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF100.92, compared to a current price of CHF74.50 — trading 26.2% below its estimated fair value. The current Days Payable is 52.89, which is 11% below median its 10-year median of 59.35 and 22.4% below the Medical Devices & Instruments industry median of 68.14. Zimmer Biomet Holdings' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Days Payable is 52.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF74.50 is trading 26.2% below its estimated GF Value™ of CHF100.92.
GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.
Key valuation signals for XSWX:ZBH:
Days Payable: 52.89 (11% below median its 10-year median of 59.35)
GF Value™: CHF100.92 vs. price of CHF74.50 (26.2% below fair value)
Industry Position: 22.4% below the Medical Devices & Instruments median (#547 of 796)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
69GF Score
Get the complete analysis for XSWX:ZBH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
